How is drug resistant TB treated? 

The treatment of drug-resistant tuberculosis (TB) has undergone significant advancements in recent years, moving away from long, painful injectable therapies toward more effective, all-oral regimens. In the United Kingdom, the clinical management of resistant strains is a highly specialized process led by multidisciplinary teams in designated centres. These specialists use advanced genomic testing to determine exactly which antibiotics the bacteria are susceptible to, allowing for a precision-medicine approach. By utilizing modern drug combinations, the NHS aims to reduce the duration of treatment while increasing cure rates and minimizing the severe side effects traditionally associated with second-line medications. 

What We’ll Discuss in This Article 

• Transition to shorter, all-oral treatment regimens. 

• The role of the BPaLM and BPaL protocols in modern care. 

• Individualised treatment pathways for complex resistance patterns. 

• Clinical management within specialist negative-pressure settings. 

• The use of Group A, B, and C drugs in long-course therapy. 

• Methods for supporting adherence, including video-observed therapy. 

• Follow-up and long-term monitoring after treatment completion. 

Modern all-oral treatment regimens (BPaLM and BPaL) 

For many patients in the UK, the standard of care has transitioned to a shorter, all-oral regimen that can be completed in six to nine months. This modern approach, often referred to as the BPaLM regimen, consists of four specific antibiotics: bedaquiline, pretomanid, linezolid, and moxifloxacin. NHS England recommends BPaLM as the preferred treatment option for eligible patients aged 14 and older with rifampicin-resistant or multidrug-resistant tuberculosis. If testing shows that the bacteria are already resistant to moxifloxacin, a three-drug version called BPaL is used instead. This shift represents a major milestone in respiratory medicine, as it removes the need for daily injections and significantly reduces the number of tablets a patient must take compared to older protocols. 

Individualised long-course treatments 

While shorter regimens are the preferred choice, some patients require an individualised long-course treatment that can last between 18 and 20 months. This pathway is typically reserved for individuals who have pre-existing resistance to the newer drugs, those who cannot tolerate specific medications due to side effects, or children who may not yet be eligible for the BPaLM protocol. The combination of treatments used is based on the results of drug-susceptibility testing and the patient’s clinical history. These longer regimens are constructed using a hierarchy of drugs categorized into Groups A, B, and C, ensuring that at least four effective antibiotics are used simultaneously to prevent any further development of resistance. 

Clinical management in specialist MDR-TB centres 

Due to the complexity of the disease, all cases of drug-resistant TB in the UK are managed by specialized centres with high-level expertise in infectious diseases. If a patient requires hospital admission, they are usually cared for in a special single room called a negative-pressure room to prevent the spread of bacteria. These rooms are designed so that air flows inward, trapping airborne droplets within a filtered system. Staff and visitors must wear specialized FFP3 respirator masks when entering the room. This intensive level of infection control is maintained until laboratory tests confirm the patient is no longer infectious, at which point they can often continue their recovery at home under close supervision. 

Drug grouping and selection for resistant TB 

The selection of medications for resistant TB follows a strict clinical hierarchy to maximize effectiveness and safety. Group A drugs are considered the most effective and include fluoroquinolones like moxifloxacin or levofloxacin, alongside newer agents like bedaquiline and linezolid. If a complete regimen cannot be formed using these, Group B drugs such as clofazimine or cycloserine are added. Finally, Group C drugs, which include medications like delamanid, pyrazinamide, or ethambutol, are utilized as companion agents. This structured approach ensures that the “core” of the treatment is built on the most powerful antibiotics available while providing the necessary support to ensure the bacteria are fully eradicated from all parts of the body. 

Supporting treatment adherence and monitoring 

Success in treating drug-resistant TB depends heavily on the patient taking every dose of medication correctly for the entire duration of the course. To support this, the NHS uses Directly Observed Therapy (DOT) or Video Observed Therapy (VOT). With VOT, patients use a secure app on their smartphone to film themselves taking their medication, which is then reviewed by their TB nurse. This flexible approach allows patients to maintain their daily routines while receiving the clinical support they need. Regular monitoring is also essential, including monthly sputum tests, blood tests to check liver and kidney function, and heart traces (ECGs) to ensure that specific medications like bedaquiline are not affecting the heart’s rhythm. 

Conclusion 

The treatment of drug-resistant tuberculosis has evolved into a highly precise, all-oral process that is significantly shorter and more effective than previous methods. By utilizing specialized protocols like BPaLM and providing care through dedicated MDR-TB centres, the NHS ensures that patients receive the most advanced antibiotics tailored to their specific infection. While the journey to a full cure is longer than for standard TB, the combination of modern medicine and robust adherence support makes a successful recovery achievable for the vast majority of patients. 

If you experience severe, sudden, or worsening symptoms, such as severe chest pain, sudden difficulty breathing, or yellowing of the skin and eyes, call 999 immediately. 

Authority Snapshot (E-E-A-T Block) 

This article provides a detailed clinical overview of the modern treatment pathways for drug-resistant tuberculosis in the United Kingdom. All information is strictly aligned with the latest clinical commissioning policies from NHS England and the evidence-based guidelines from the National Institute for Health and Care Excellence (NICE). The content has been authored by a medical writing team and reviewed by Dr. Stefan Petrov, a UK-trained physician, to ensure it meets the highest standards of accuracy and clinical safety.